Palliative Therapie des Pankreaskarzinoms

Schlüsselwörter

Pankreaskarzinom - Chemotherapie - Gemcitabin

Key words

pancreatic cancer - chemotherapy - gemcitabine

Literatur

• 1 Abou-Alfa G K, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian N S, Feit K, Ackerman J, De Jager R L, Eckhardt S G, O’Reilly E M. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.  J Clin Oncol. 2006;  24 4441-4447
• 2 Berlin J D, Catalano P, Thomas J P, Kugler J W, Haller D G, Benson A B. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.  J Clin Oncol. 2002;  20 3270-3275
• 3 Bramhall S R, Rosemurgy A, Brown P D, Bowry C, Buckels J A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.  J Clin Oncol. 2001;  19 3447-3455
• 4 Burris H A 3 rd, Moore M J, Andersen J, Green M R, Rothenberg M L, Modiano M R, Cripps M C, Portenoy R K, Storniolo A M, Tarassoff P, Nelson R, Dorr F A, Stephens C D, Von Hoff D D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.  J Clin Oncol. 1997;  15 2403-2413
• 5 Glimelius B, Hoffman K, Sjoden P O, Jacobsson G, Sellstrom H, Enander L K, Linne T, Svensson C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.  Ann Oncol. 1996;  7 593-600
• 6 Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.  J Clin Oncol. 2006;  24 3946-3952
• 7 Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun M J. Cancer statistics, 2006.  CA Cancer J Clin. 2006;  56 106-130
• 8 Larsson S C, Permert J, Hakansson N, Naslund I, Bergkvist L, Wolk A. Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts.  Br J Cancer. 2005;  93 1310-1315
• 9 Louvet C, Labianca R, Hammel P, Lledo G, Zampino M G, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, Gramont de A. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.  J Clin Oncol. 2005;  23 3509-3516
• 10 Lutz M P, Koniger M, Muche R, Ellenrieder V, Steinkamp M, Adler G, Gress T M. A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer.  Z Gastroenterol. 1999;  37 993-997
• 11 Moertel C G, Frytak S, Hahn R G, O’Connell M J, Reitemeier R J, Rubin J, Schutt A J, Weiland L H, Childs D S, Holbrook M A, Lavin P T, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas H O, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson J M, Zamcheck N, Novak J W. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.  Cancer. 1981;  48 1705-1710
• 12 Oettle H, Richards D, Ramanathan R K, Laethem J L, Peeters van M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler H L. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.  Ann Oncol. 2005;  16 1639-1645
• 13 Petty R D, Nicolson M C, Skaria S, Sinclair T S, Samuel L M, Koruth M. A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity.  Ann Oncol. 2003;  14 1100-1105
• 14 Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.  Lancet Oncol. 2005;  6 369-376
• 15 Rocha Lima C M, Green M R, Rotche R, Miller W H, Jeffrey G M, Cisar L A, Morganti A, Orlando N, Gruia G, Miller L L. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.  J Clin Oncol. 2004;  22 3776-3783
• 16 Statistisches Bundesamt .Krebs in Deutschland. Häufigkeit und Trends. Saarbrücken 2002
• 17 Steinberger M, Beyer A. Tumorschmerzen Der konkrete Fall, Diagnostik und Therapie.  Dtsch med Wochenschr. 2005;  130 1449-1456
• 18 Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.  J Clin Oncol. 2003;  21 3402-3408
• 19 Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.  Invest New Drugs. 2005;  23 369-375
• 20 Ulrich-Pur H, Raderer M, Verena Kornek G, Schull B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Scheithauer W. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.  Br J Cancer. 2003;  88 1180-1184
• 21 Van Cutsem E, Velde van de H, Karasek P, Oettle H, Vervenne W L, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.  J Clin Oncol. 2004;  22 1430-1438
• 22 Xiong H Q, Rosenberg A, LoBuglio A, Schmidt W, Wolff R A, Deutsch J, Needle M, Abbruzzese J L. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.  J Clin Oncol. 2004;  22 2610-2616
• 23 Yip D, Karapetis C, Strickland A, Steer C B, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.  Cochrane Database Syst Rev. 2006;  3 CD002093